Biocompatible pH-responsive nanoparticles with a core-anchored multilayer shell of triblock copolymers for enhanced cancer therapy by Ellis, E et al.
This journal is©The Royal Society of Chemistry 2017 J. Mater. Chem. B, 2017, 5, 4421--4425 | 4421
Cite this: J.Mater. Chem. B, 2017,
5, 4421
Biocompatible pH-responsive nanoparticles with
a core-anchored multilayer shell of triblock
copolymers for enhanced cancer therapy†
Elizabeth Ellis,abc Kangyi Zhang,c Qianyu Lin,d Enyi Ye,c Alessandro Poma,a
Giuseppe Battaglia,ae Xian Jun Loh cd and Tung-Chun Lee *ab
Drug nanocarriers are synthesised via a facile self-assembly approach
using gold nanoparticles (Au NPs) as a structural core. The nano-
carriers feature a multilayer shell of POEGMA–PDPA–PMPC triblock
copolymers with a chain-end thiol functional group for anchoring to
the Au NP surface. This water-soluble triblock copolymer was
synthesised via atom transfer radical polymerisation (ATRP) from a
bi-functional initiator containing a disulphide bridge. The resultant
nanocarriers exhibit high biocompatibility plus excellent colloidal
stability and antifouling capability in bio-media (50% PBS/FBS). Encap-
sulation and release of a hydrophobic drug can be effectively triggered
by a pH-stimulus. Meanwhile drug-loaded nanocarriers show enhanced
efficacy towards cancer cells compared to plain drug.
Compartmentalised micro and nanostructures are abundant in
nature and are essential to many processes in living organisms,
such as intercellular signaling mediated by exosomes,1 and
storage and release of materials by vacuoles. Inspired by nature,
diﬀerent kinds of artificial compartmentalised nanostructures
have been developed. A large group of these artificial nanostruc-
tures have been employed for drug delivery purposes, including
micelles,2,3 vesicles,4,5 metal–organic frameworks6 and inorganic
nanoparticles.7 Encapsulating drugs within nanostructures
increases their solubility and circulation time and can reduce
side effects by selective release into unhealthy areas, limiting
damage to healthy tissues.8,9 For example, pH responsive nano-
structures are often exploited for release of drugs into areas of low
pH through protonation and acid catalysed bond cleavage.10,11
For practical applications, chemical composition of the
substituent materials of artificial nanostructures have to be
biocompatible. In this context, block copolymers based on
poly(oligo(ethylene glycol)methyl ether methacrylate) POEGMA,
poly(2-(diisopropyl amino)ethyl methacrylate) PDPA and poly(2-
(methacryloyloxy)ethyl phosphorylcholine) PMPC show particular
advantages because of their high biocompatibility and ease of
synthesis.12 Polymersomes of PMPC–PDPA and POEGMA–PDPA
have been used for delivery of anticancer drugs,13,14 proteins,15
DNA16 and antibiotics.17 In these systems, the pH-responsive
hydrophobicity of PDPA has been exploited for rapid dis-
assembly of nanocarriers in mildly acidic environments within
cells endosomes.16,18 In addition PMPC has been shown to
interact with scavenger B receptors on cell membranes, which
are overexpressed on cancer cells, facilitating entry of polymer-
somes into the cells.19 Nevertheless, the above and similar types
of nanocarriers can be demanding to make and handle owing to
the dynamic nature of these systems.
Anchoring functional polymers onto the surface of gold
nanoparticles (Au NPs) via self-assembly has been considered a
powerful strategy for producing multifunctional drug carriers.20 In
addition to their low cytotoxicity, ease of synthesis and unique
plasmonic properties that can be exploited for theranostic and
synergistic therapies,21,22 Au NPs can serve as a structural core for
forming well-defined, stable nanostructures, in contrast to some
other self-assembled structures. For instance, non-crosslinked, low
molecular weight micelles are prone to dissociation below their
critical micelle concentration, resulting in premature release of
their payload.23 In the context of biomedical applications, Au
NPs are conventionally coated by polyethylene glycol (PEG)
which may suﬀer from fouling at high protein concentration.24
Herein we use Au NPs as a structural core for anchoring
triblock copolymers of POEGMA–PDPA–PMPC via a facile assembly
approach to form antifouling, pH-responsive nanocarriers (Fig. 1a).
POEGMA is a less-coiled block that favours the formation of a
dense inner shell on the Au NPs. It also enhances the solubility
of the intermediate polymer chains during polymerisation. The
PDPA layer can serve as a pH-responsive sponge for hydrophobic
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drug encapsulation and release (Fig. 1b and c). Doxorubicin, a
highly toxic cancer drug that has serious side effects such as
cardiotoxicity,25 is used as a model drug. The undesirable side
effects can be reduced by incorporating the drug into a wide
variety of nanostructures including hydrogels, liposomes and
polymeric micelles, for improved selectivity.26 The zwitterionic
PMPC outer corona is designed to enhance the colloidal stability
across different pH and ionic strength. In addition, PMPC is
also known to be antifouling owing to its high degree of
hydration in aqueous media.27 We demonstrate that these
nanocarriers indeed exhibit high biocompatibility, notable
colloidal stability plus antifouling capability in concentrated
bio-media, and enhancement in drug efficacy towards cancer
cells. To the best of our knowledge, this represents the first
example of anchoring POEGMA–PDPA–PMPC based polymer
onto Au NPs and of studying the resultant drug delivery
performance in cancer cells.
POEGMA–PDPA–PMPC triblock copolymers were first pre-
pared as outlined in Fig. 2a based on previously reported
methods.28 Atom transfer radical polymerisation (ATRP) via
sequential addition from a bi-functional initiator containing a
disulphide bridge was used. OEGMA (Mn = 500 g mol
1) was
polymerised first, followed by addition of DPA and then MPC.
Block ratio and purity were confirmed by nuclear magnetic
resonance (NMR) spectroscopy and gel permeation chromato-
graphy (GPC), using conversion measurements and comparison
of peak integrals (Fig. S1, ESI†). Reducing conditions during
purification directly cleaved the disulphide bridge in the initiator
as confirmed by GPC (Fig. S2, ESI†), leaving free thiol groups on
the POEGMA termini of the polymer.
Citrate-coated Au NPs (d = 15.5  2.5 nm), prepared via the
Turkevich method, were then coated with the polymer by
displacement of citrate ions with thiol groups on the end of
the polymer chains. Au NPs were added to a polymer solution
containing a large excess of polymer at pH 2.3, where the
pH-sensitive amino groups of the PDPA block are fully protonated
and the polymer chains fully extended to avoid micellisation of
the polymer. NaCl was subsequently added to enhance the
packing of the polymer shell by reducing the charge repulsion
between protonated amines on the PDPA block. The resultant
core–shell nanocarriers can be readily purified by centrifuga-
tion because of the high-density Au NP core. Following removal
of excess polymer, NaCl and displaced citrate by centrifugation
and redispersion, the polymer coating was characterised and
confirmed by UV-vis spectroscopy, dynamic light scattering
(DLS) measurements and transmission electron microscopy
(TEM) as shown in Fig. 2b–d.
The UV-vis spectrum shows a 4 nm red shift of the localised
surface plasmon resonance (LSPR) peak of Au NPs upon polymer
conjugation (Fig. 2b). The shift can be attributed to the increase
in refractive index of the media (represented by the polymer
coating) immediately surrounding the Au NP. Meanwhile, DLS
reveals an increase in hydrodynamic diameter (Dh) of 46 nm upon
polymer conjugation at pH 2.3. This implies the thickness of the
fully protonated polymer shell is 23 nm, consistent with the
theoretical, fully extended polymer length of 27.9 nm. In TEM
images (Fig. 2d) of a sample prepared using phosphotungstic acid
(PTA) negative staining, the polymer shell is visible as a white
halo around the dark Au NPs, with a thickness of 4.0  0.9 nm.
Fig. 1 (a) Formation of compartmentalised nanocarriers via self-assembly
of POEGMA–PDPA–PMPC triblock copolymers on the surface of Au NPs.
(b) Encapsulation and release of hydrophobic drugs by the nanocarriers
can be gated by the pH level of surrounding media, via the (c) change in
hydrophobicity of the PDPA block upon (de)protonation.
Fig. 2 (a) Synthetic scheme of thiolated triblock polymers and their
conjugation to Au NPs. (b) UV-vis spectra and (c) hydrodynamic diameter
(Dh as measured by DLS) of Au NPs before (grey dot) and after (red solid)
polymer conjugation. (d) Top: TEM image of polymer-coated Au NPs. Inset
showing a false-colour image of a selected NP. Bottom: Corresponding
line profile of the inset.
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The grafting density is estimated to be B0.11 chains per nm2
(i.e. polymer footprint B8.8 nm2 and B86 chains per NP). In
line with our expectation, the shell thickness determined by
TEM is smaller than that given by DLS because the former was
measured in a dry state in which the polymer shell shrank
significantly upon dehydration, while the latter was determined
in a fully hydrated state (Tables S1 and S2, ESI†).
Colloidal stability of nanocarriers in bio-media is an impor-
tant property as it aﬀects the uptake eﬃciency by cells.7 Citrate-
stabilised Au NPs are prone to aggregation upon an increase in
ionic strength of the media owing to the corresponding decrease
in charge repulsion between them.29 Similarly, they are also prone
to protein fouling, which can cause aggregation and change in
surface properties, potentially leading to immune response of
patients.30 Zwitterionic materials, in particular PMPC, have been
shown to eﬀectively reduce protein fouling at high serum
concentrations.24,27,29 To investigate the colloidal stability of the
polymer-coated Au NPs in these conditions, solutions of the NPs
were mixed at a 1 : 1 ratio with phosphate buﬀered saline (PBS)
and fetal bovine serum (FBS). PBS has a high salt concentration
which causes citrate-coated NPs to aggregate31 (Fig. S5 and S6,
ESI†) and FBS contains large amounts of proteins such as bovine
serum albumin. UV-vis and DLS were used to monitor the
solutions for aggregation and protein fouling. If aggregation
occurs, the LSPR peak of the Au NPs will broaden and red shift
due to plasmonic coupling between aggregated Au NPs. If
aggregation is severe, the optical extinction decreases because
of precipitation of NPs out of solution. In contrast to citrate-
stabilised Au NPs, polymer-coated nanocarriers show no signifi-
cant change in the LSPR peak position in either medium
(Fig. 3a). Antifouling of the nanocarriers is further verified by
the DLS data which shows no significant change in hydro-
dynamic diameter when the NPs are in 50% FBS (Fig. S7a, ESI†).
In contrast, citrate-coated Au NPs show a size increase of 39.5 nm
in 50% FBS (Fig. S7b, ESI†), indicating the occurrence of protein
fouling as expected.31 It is noted that this does not quantitatively
discard protein interactions with the nanocarriers.
The response of the nanoparticles to pH changes was then
investigated. The hydrodynamic diameter of the polymer-
coated NPs was measured at pH 2.3 and pH 7.0 at 25.0 1C.
A size decrease of 3.4 nm was observed upon an increase in pH
from 2.3 to 7.0 (Fig. 3b). The pKa of the PDPA is approximately 6
at 37 1C with values varying from 5.75 at 50 1C to 7.6 at 5 1C.18
The positive charges along the chain repel each other and this
is suﬃcient to overcome the entropic tendency of the polymer
to coil. Hence PDPA chains are expected to be stretched. An
increase in pH leads to deprotonation of the amino groups and
the PDPA segment of the polymer chain becomes hydrophobic
as it is no longer charged (Fig. 1c). This means that PDPA
chains can now relax to a more coiled configuration with a
consequent decrease in size. Attachment of polymer on Au NPs
via the numerous amino groups of the PDPA block is unlikely
because the PDPA chains would then be wrapping around the
Au NP as opposed to extending from the Au NP surface.
Therefore, upon deprotonation, no or very little contraction
would be observed in this scenario.
Drug encapsulation and triggered release by the nano-
carriers were investigated using the cancer drug doxorubicin
(DOX). DOX is a hydrophobic drug (log P = 1.27) and its water
solubility increases slightly in the hydrochloric acid form. DOX-
loading was performed by introducing DOX during the polymer
coating step at pH 2.3, followed by incubation at pH 7.2. Excess
DOX and polymer were then removed by centrifugation and
redispersion. By measuring the decrease in fluorescence of the
resultant supernatant, the encapsulation eﬃciency, i.e. (amount
of DOX encapsulated/amount added)  100%, is calculated to
be B37%, and the drug loading is estimated to be B47%.
Triggered release experiments were performed by incubating 3
sets of DOX-loaded nanoparticles (NP-DOX) in the dark at 37 1C,
pH 7.2 for 24 hours. Periodically, samples were taken from each
vial and centrifuged. Fluorescence of the supernatant was then
measured (Fig. 4a). At pH = 7.2, no release of DOX was observed
for the first 24 hours. This is attributed to the long length and
highly hydrophobic nature of the PDPA block. After 24 hours, the
pH of the solution was decreased toB4.0 so that the PDPA shell
would be protonated and become hydrophilic, triggering the
release of DOX as shown by the fluorescence data.
Finally, cell studies were carried out to investigate the
biocompatibility of the nanocarriers and their ability to kill
cancer cells. As a control, a biocompatibility assay verifies that the
nanocarriers alone are not toxic to healthy cells (Fig. S8, ESI†).
MCF-7 breast cancer cells were then treated with DOX-loaded
nanocarriers and their cell-killing eﬃciency was compared to
free doxorubicin at the same concentration. The cell viability after
24 hours was significantly lower for the NP-DOX than for plain
DOX (Fig. 4b). Hence, these safe nanocarriers have the potential to
increase the eﬃcacy of chemotherapy. Drug uptake by cells was
verified by fluorescence microscopy. Both NP-DOX and DOX
resulted in drug internalisation by MCF-7 after one-hour incuba-
tion (red fluorescence in Fig. 4c and d). This shows that DOX in
the NP-DOX construct remains active and eﬃcacious.
In conclusion, drug nanocarriers with a multifunctional
polymer shell have been synthesised via a facile self-assembly
approach using Au NPs as a structural core. The POEGMA–
PDPA–PMPC triblock copolymers were synthesised via sequen-
tial ATRP from a disulphide initiator. These nanocarriers are
Fig. 3 (a) Colloidal stability and antifouling of nanocarriers in bio-media.
UV-vis spectra of polymer-coated NPs in deionised water (grey solid), 50%
PBS (red dash), and 50% FBS (blue dot, FBS background subtracted). Inset
shows a photo of the samples. (b) pH-Responsiveness of the nanocarriers.
Hydrodynamic diameter of polymer-coated Au NPs at pH 2.3 (red solid)
and pH 7.0 (blue dot) at 25 1C.
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notably stable, antifouling and biocompatible owing to the
highly-hydrated, zwitterionic outer corona. The pH-responsive
middle layer allows encapsulation and triggered release of a
hydrophobic drug in a controllable manner. Proof-of-concept
experiments show that the nanocarriers can enhance the efficacy
of hydrophobic drug towards cancer cells, resulting in a significant
decrease in cell viability compared to the control using unencap-
sulated drug. Following further studies, the nanocarriers have
potential to be used for co-delivery of hydrophobic and hydrophilic
drugs by utilising both the PDPA and the POEGMA layers of
the shell. In light of theranostics, functional properties of the
inorganic NP core can be simultaneously exploited, for instance in
photothermal therapy, and in the case of hybrid nanoparticles,
refractive index32 and rheology33 sensing at the nanoscale.
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